Entity Common Stock, Shares Outstanding of Propanc Biopharma, Inc. from Q1 2012 to Q3 2025

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Propanc Biopharma, Inc. quarterly Entity Common Stock, Shares Outstanding history and change rate from Q1 2012 to Q3 2025.
  • Propanc Biopharma, Inc. Entity Common Stock, Shares Outstanding for the quarter ending 24 Sep 2025 was 12.8M shares, a 98.1% decline year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Propanc Biopharma, Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 12.8M -675M -98.1% 24 Sep 2025 10-K 29 Sep 2025
Q1 2025 11.6M -40.5M -77.7% 15 May 2025 10-Q 15 May 2025
Q4 2024 15.4K* 12 Feb 2025 10-Q 14 Feb 2025
Q3 2024 688M +673M +4538% 25 Sep 2024 10-K 30 Sep 2024
Q1 2024 52.1M -3.24B -98.4% 20 Feb 2024 10-Q 20 Feb 2024
Q3 2023 14.8M -662M -97.8% 27 Sep 2023 10-K 28 Sep 2023
Q1 2023 3.29B 12 May 2023 10-Q 15 May 2023
Q4 2022 1.76B +1.7B +2772% 09 Feb 2023 10-Q 10 Feb 2023
Q3 2022 677M +636M +1548% 26 Sep 2022 10-K 28 Sep 2022
Q2 2022 122M 16 May 2022 10-Q 16 May 2022
Q4 2021 61.4M +57.8M +1589% 14 Feb 2022 10-Q 14 Feb 2022
Q3 2021 41.1M -648M -94% 24 Sep 2021 10-K 28 Sep 2021
Q1 2021 5.97M -41.1M -87.3% 14 May 2021 10-Q 14 May 2021
Q4 2020 3.64M -1.55M -29.9% 09 Feb 2021 10-Q 12 Feb 2021
Q3 2020 689M +688M +58759% 28 Sep 2020 10-K 01 Oct 2020
Q1 2020 47.1M -374M -88.8% 11 May 2020 10-Q 15 May 2020
Q4 2019 5.19M -329M -98.4% 13 Feb 2020 10-Q 14 Feb 2020
Q3 2019 1.17M -161M -99.3% 02 Oct 2019 10-K 15 Oct 2019
Q1 2019 421M +382M +998% 10 May 2019 10-Q 15 May 2019
Q4 2018 334M +313M +1476% 14 Feb 2019 10-Q 14 Feb 2019
Q3 2018 162M +156M +2397% 17 Sep 2018 10-K 17 Sep 2018
Q1 2018 38.3M +34.6M +921% 10 May 2018 10-Q 10 May 2018
Q4 2017 21.2M -893M -97.7% 08 Feb 2018 10-Q 09 Feb 2018
Q3 2017 6.49M -783M -99.2% 28 Sep 2017 10-K 28 Sep 2017
Q1 2017 3.75M -718M -99.5% 08 May 2017 10-Q 08 May 2017
Q4 2016 914M +439M +92.3% 14 Feb 2017 10-Q 14 Feb 2017
Q3 2016 790M +433M +121% 26 Sep 2016 10-K 28 Sep 2016
Q1 2016 722M +530M +277% 11 May 2016 10-Q 16 May 2016
Q4 2015 476M +385M +423% 09 Feb 2016 10-Q 16 Feb 2016
Q3 2015 357M +274M +333% 30 Sep 2015 10-K 30 Sep 2015
Q1 2015 192M 16 Feb 2015 10-Q 17 Feb 2015
Q4 2014 91M +18.3M +25.1% 19 Nov 2014 10-Q 19 Nov 2014
Q3 2014 82.4M +11M +15.3% 14 Oct 2014 10-K 14 Oct 2014
Q2 2014 72.7M +2.05M +2.91% 19 May 2014 10-Q 20 May 2014
Q4 2013 72.7M -1.01M -1.37% 10 Feb 2014 10-Q 14 Feb 2014
Q3 2013 71.5M -1.53M -2.09% 11 Oct 2013 10-K 15 Oct 2013
Q2 2013 70.6M -2.15M -2.95% 20 May 2013 10-Q 20 May 2013
Q1 2013 73M +985K +1.37% 19 Feb 2013 10-Q 20 Feb 2013
Q4 2012 73.7M 19 Nov 2012 10-Q 19 Nov 2012
Q3 2012 73M 11 Oct 2012 10-K 15 Oct 2012
Q2 2012 72.8M 18 May 2012 10-Q 21 May 2012
Q1 2012 72M 29 Feb 2012 10-Q/A 07 Mar 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.